ClinConnect ClinConnect Logo
Search / Trial NCT03151018

Effect and Efficacy of Onyx™, Zotarolimus-eluting Stent for Coronary Atherosclerosis

Launched by SEOUL NATIONAL UNIVERSITY HOSPITAL · May 10, 2017

Trial Information

Current as of May 08, 2025

Unknown status

Keywords

Coronary Artery Disease Percutaneous Coronary Intervention Zotarolimus Eluting Stents

ClinConnect Summary

Secondary endpoints are

1. Stent thrombosis-24 hours(acute), 30 days(subacute), 1 year(late), every 1 year till 3 years(very-late) after index PCI (percutaneous coronary intervention),
2. Target vessel failure
3. Composite rate of cardiac death and any MI, 3 years
4. Composite rate of all death and any MI
5. Composite rate of all death, any MI, and any repeat revascularization
6. Compliance and therapy interruptions with prescribed adjunctive antiplatelet therapy
7. Clinical device and procedural success

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age above 19
  • Patients who received PCI with Resolute Onyx™ stent(s)
  • Exclusion Criteria:
  • None

About Seoul National University Hospital

Seoul National University Hospital (SNUH) is a leading medical institution in South Korea, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent clinical trial sponsor, SNUH integrates cutting-edge scientific inquiry with patient-centered care, facilitating the development of novel therapies and treatment protocols. The hospital boasts a diverse range of specialized departments and a robust infrastructure for conducting clinical studies, ensuring rigorous adherence to ethical standards and regulatory compliance. By fostering collaboration among multidisciplinary teams, SNUH aims to contribute significantly to global medical advancements and improve patient outcomes.

Locations

Seongnam, , Korea, Republic Of

Seoul, , Korea, Republic Of

Seoul, , Korea, Republic Of

Seoul, , Korea, Republic Of

Seoul, , Korea, Republic Of

Seoul, , Korea, Republic Of

Jinju, , Korea, Republic Of

Suwon, , Korea, Republic Of

Seoul, , Korea, Republic Of

Pusan, , Korea, Republic Of

Seoul, , Korea, Republic Of

Cheonan, , Korea, Republic Of

Chonju, , Korea, Republic Of

Gwangju, , Korea, Republic Of

Jeonju, , Korea, Republic Of

Seoul, , Korea, Republic Of

Gwangju, , Korea, Republic Of

Busan, , Korea, Republic Of

Goyang, , Korea, Republic Of

Patients applied

0 patients applied

Trial Officials

Hyo-soo Kim, MD, PhD

Study Chair

Seoul National University Hospital

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials